The intra-aortic balloon pump (IABP) has been used as a cardiac assist device in various clinical situations since 1968 on the basis of the physiological principles and observational data, with little randomized data until recently.
INTRODUCTION
The intra-aortic balloon pump (IABP) has been used as a cardiac assist device in cardiogenic shock since 1968 [1] . Over the years, case reports and observational studies have described the use of IABP in high-risk myocardial infarction (MI), MI complicated by cardiogenic shock, acute severe mitral incompetence or ventricular septal rupture and for prophylactic support ahead of high-risk percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. In this review, we will summarize the recent data from randomized controlled trials (RCTs) and meta-analyses which cast doubt over the efficacy of IABP for some indications whilst providing qualified support for others. IABP should be considered with other percutaneous left ventricular assist devices including Tandem Heart, Impella and extracorporeal membrane oxygenation, although these are beyond the scope of this review.
HISTORY
The principle of aortic counterpulsation was first described by Kantrowitz [2] in 1952 in a dog model, in which the hemidiaphragm was wrapped around the thoracic aorta and electrically stimulated via the phrenic nerve in diastole. In 1962, Moulopoulos et al. [3] developed the modern intra-aortic device with a balloon mounted on a flexible double-lumen catheter whose inflation and deflation in the descending aorta were timed to the cardiac cycle. In 1968, Kantrowitz et al. [1] reported improved systemic arterial and central venous pressures as well as urine output with the use of an IABP in patients with cardiogenic shock. In 1971, Krakauer et al. [4] , working with Kantrowitz, reported their experience in 30 patients who received an IABP for cardiogenic shock secondary to MI refractory to medical therapy. A total of 25 of 30 patients achieved haemodynamic stabilization and reversal of shock with IABP, and survival was significantly better in those who received an IABP early after the onset of shock. IABP insertion via a femoral cutdown has been largely replaced by percutaneous insertion, first described by Bregman et al. [5] in 1980.
The modern console pump delivers helium to the balloon for diastolic inflation to increase diastolic pressure and coronary blood flow, thereby increasing myocardial oxygen supply. Rapid presystolic deflation reduces left ventricular afterload, reducing myocardial oxygen demand. Improvement in mean blood pressure may result and assist with general organ perfusion [6, 7] (Fig. 1) .
INTRA-AORTIC BALLOON PUMP IN MYOCARDIAL INFARCTION WITHOUT SHOCK
Animal studies have suggested that unloading of the left ventricle with IABP prior to reperfusion reduces infarct size and is associated with larger amount of salvaged myocardium [8] [9] [10] . Primary percutaneous reperfusion for patients with acute ST-segment elevation myocardial infarction (STEMI) has been shown to reduce mortality and is considered the standard of care when available [11] . Studies from the pre-PCI era did show an improved clinical outcome with IABP [12, 13] . However, more recent studies have not demonstrated efficacy for IABP as adjunctive therapy compared with standard treatment alone in high-risk STEMI patients treated with primary PCI [14, 15] (Fig. 2) . The counterpulsation reduces infarct size pre-PCI in AMI trial randomized 337 patients with anterior STEMI without cardiogenic shock to IABP inserted prior to PCI and continued for at least 12 h vs. PCI alone. There was no difference in the primary outcome measure of infarct size on cardiac MRI 3-5 days after PCI. Although the study was not powered for mortality, the 6-month mortality was 1.9% in the IABP-treated
KEY POINTS
IABP increases diastolic blood pressure and coronary perfusion in addition to reducing left ventricular afterload and myocardial oxygen consumption.
Recent trials have failed to demonstrate benefit for IABP in MI treated with PCI with or without shock.
Small trials support the use of IABP in niche indications of acute ischaemic mitral regurgitation, ventricular septal rupture and refractory ventricular arrhythmias.
Conflicting data precludes a strong recommendation on the use of prophylactic IABP in high-risk PCI or highrisk CABG.
Large-scale randomized trials are needed to establish appropriate indications and optimal timing of IABP use. Clinical trials patients and 5.2% in those with PCI alone (P ¼ 0.12) [14] . Recent meta-analyses have demonstrated an increase in the incidence of major bleeding and stroke with IABP use in high-risk STEMI patients [16] [17] [18] . At this stage, there is no evidence to support the routine use of IABP in MI without cardiogenic shock. Further trials powered to clinical endpoints should be considered, particularly in high-risk subgroups.
INTRA-AORTIC BALLOON PUMP FOR CARDIOGENIC SHOCK COMPLICATING MYOCARDIAL INFARCTION
Cardiogenic shock arises in 7-10% of acute MIs, with mortality of 70-80% over previous decades [19] . Although contemporary reperfusion with primary PCI coupled with modern coronary care and optimal medical therapy has improved outcome, the survival of patients with cardiogenic shock at 1 year remains in the region of 50% [20] . IABP is the most widely used form of mechanical haemodynamic support in this setting and until recently attracted a strong recommendation in guideline statements.
In the most recently published three metaanalyses of observational studies and RCT of IABP in cardiogenic shock [17,18,21 & ], Romeo et al. report a 29% mortality reduction in STEMI without reperfusion therapy and an 18% reduction in STEMI treated with thrombolysis. In contrast, a 6% increase in mortality was associated with IABP therapy in STEMI patients treated with primary PCI. This suggests that the benefit of IABP may be dependent upon other therapies and may be limited in conjunction with primary PCI. A German registry study concerning 1913 shocked MI patients treated with PCI between 2006 and 2011 [22] found significantly higher inhospital mortality amongst 487 patients treated with IABP than in the 1444 patients treated without IABP (43.5 vs. 37.4%; P ¼ 0.004). These studies, which suggest that IABP may increase mortality in shocked MI patients treated with primary PCI, are potentially limited by the selection bias, highlighting the need for randomized data.
The Intra-aortic Balloon Pump in Cardiogenic Shock (IABP-SHOCK) trial randomized 45 patients and found no significant difference in Acute Physiology and Chronic Health Evaluation II (APACHE II) scores in those patients assigned to IABP compared with control. IABP was associated with a significant reduction in serial brain natriuretic peptide levels [23] .
In the larger Intra-aortic Balloon Pump in Cardiogenic Shock 2 trial (IABP-SHOCK II), the same investigators randomized 600 patients with cardiogenic shock complicating acute MI, for whom an early [16] CRISP 2011 [14] Romeo 2013 [17] Romeo 2013 [21*] Romeo 2013 [24] BCIS-1 2010 [22] Romeo 2013 received IABP. The mortality of shocked patients was 61% with IABP and 100% without IABP (P ¼ 0.04). Mortality in those unstable but without shock was 20 and 27%, respectively (P ¼ 0.7). Perioperative mortality was 11% in those with IABP and 88% in those without IABP (P < 0.001). Such observational data may be considered compelling. The low incidence of these complications and high risk of haemodynamic instability may make it difficult to mount a randomized trial of IABP for this indication.
INTRA-AORTIC BALLOON PUMP FOR INTRACTABLE VENTRICULAR ARRHYTHMIAS
The use of IABP for intractable ventricular arrhythmias has long been described [34, 35] , but is used infrequently. A single-centre retrospective review on the use of IABP in 21 patients with medically refractory ventricular arrhythmias was described by Fotopoulos et al. [36] in 1999. All patients had impaired left ventricular systolic function and 18 had evidence of coronary artery disease, with two having idiopathic dilated cardiomyopathy and one with cardiac amyloidosis. All patients had been tried on intravenous amiodarone, with 17 receiving multiple pharmacological agents. With IABP support, 18 out of 21 patients were stabilized, with 14 of those patients having complete abolition of arrhythmias and the remaining four having significant reduction. Out of the three patients with nonischaemic cardiomyopathy, two had improvement in their ventricular arrhythmia with IABP support. Goyal et al. [37] recently described a case of nonischaemic cardiomyopathy in which use of IABP resulted in immediate cessation of refractory ventricular tachycardia.
The mechanism by which IABP improves control of ventricular arrhythmia is unclear. In those with ischaemic heart disease, IABP may improve coronary blood flow and reduce afterload, thereby reducing ischaemia [36, 37] . However, patients with normal coronary arteries also benefit from IABP. It has been suggested that IABP reduces potentially proarrhythmic adrenergic drive [36] . Animal studies in dogs have demonstrated that increased afterload increases ventricular ectopy. By reducing afterload and myocardial stretch, IABP could potentially make the myocardium less arrhythmogenic [38] .
Studies supporting the use of IABP for intractable ventricular arrhythmias are small retrospective case series or case reports. Nonetheless, published reports are promising and support the use of IABP in this setting, especially when all other management options are exhausted.
PROPHYLACTIC INTRA-AORTIC BALLOON PUMP FOR HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION
The use of elective IABP to support haemodynamically stable patients undergoing high-risk PCI is well described [39] . There is currently no universal definition of this high-risk cohort, and trials variably include patients with severely impaired left ventricular function, large territory of at-risk myocardium and planned multivessel interventions. The AHA and ACC guidelines give a Class IIb recommendation for its use in high-risk PCI and the ESC guidelines only recommend it for unstable patients [29, 30] .
Prophylactic IABP insertion for high-risk PCI was reported to be effective in two observation studies by Briguori et al. [40, 41] . These results were not supported by the Balloon Pump Assisted Coronary Intervention Study (BCIS-1), the first RCT to look at the effectiveness of elective IABP use in patients undergoing high-risk PCI without shock [42] . The trial recruited 301 patients requiring PCI with severe left ventricular dysfunction (ejection fraction <30%) and a large amount of myocardium at risk from diseased vessels. They were randomized to prophylactic IABP insertion prior to PCI or no IABP. The primary endpoint was a composite of major adverse cardiovascular and cerebrovascular events (MACCE). The secondary endpoints were all-cause mortality at 6 months, major procedural complications, bleeding and access-site complications.
The study did not detect a difference in MACCE outcomes between the study groups. The prophylactic IABP group had more minor bleeding, but no difference in major bleeding. The prophylactic group had significantly fewer procedural complications (1.3 vs. 10.7%), which was driven mainly by less prolonged procedural hypotension and haemodynamic instability. Rescue IABP was required in 12% of patients assigned to no planned IABP insertion, with the main reason for cross-over being procedural hypotension. In the study, there appeared to be a higher rate of MACCE in the rescue IABP group and longer inhospital stay and duration of IABP support. A similar 15% cross-over rate was seen in the previous observational study by Briguori et al. [41] .
The trial demonstrated a nonsignificant trend towards a mortality benefit with elective IABP at 6 months (4.6 vs. 7.4%; P ¼ 0.32). Long-term followup to 51 months demonstrated a 34% relative reduction in mortality in favour of the elective IABP group (7.9 vs. 12.1%; P ¼ 0.039) [43 benefit of prophylactic IABP at reducing in-hospital mortality and MACCE in high-risk patients undergoing PCI [44 & ]. The results of this RCT and several observational studies do not support the general use of elective IABP before high-risk PCI. However, it remains possible that high-risk subgroups, underrepresented in the published trials, may benefit from prophylactic IABP. The higher rate of adverse events in those 'crossing-over' to IABP also suggests there may be a subgroup who would benefit from prophylactic rather than rescue IABP. Lastly, the late mortality benefit in BCIS-1 is intriguing and warrants further study in a larger trial powered for clinical endpoints.
PROPHYLACTIC INTRA-AORTIC BALLOON PUMP FOR HIGH-RISK CORONARY ARTERY BYPASS GRAFT
The role of IABP postcardiac surgery in patients with low cardiac output was first described 40 years ago and is currently well established [45] ; however, the benefit of prophylactic insertion of IABP in high-risk stable patients remains unclear, with conflicting results from a small number of trials over the last 2 decades. Various conditions, including poor left ventricular function, left main disease, diffuse coronary disease and redo surgery, have been suggested as indications for prophylactic IABP [46] [47] [48] [49] [50] [51] .
A Cochrane systemic review by Theologou et al. in 2011 analysed data from a total of 255 patients from six randomized control trials looking at preoperative IABP insertion in high-risk patients before on-pump CABG [45] [46] [47] [48] [49] [50] [51] [52] . There were fewer inhospital deaths [3.8 vs. 26 .1%, odds ratio (OR) 0.18 (0.08-0.41); P < 0.0001] and fewer patients with low cardiac index (<2.0 l/min/m 2 ) in the IABP group compared with the control group [46] . Five of the six RCTs come from the same centre and principal investigator, raising an issue about the broad applicability of these results.
A recently published single-centre randomized control trial by Ranucci et al. [53 & ] attempted to address the question of preoperative IABP insertion in haemodynamically stable patients with a left ventricular ejection fraction less than or equal to 35% about to undergo on-pump CABG. Patients randomized to the intervention group had the IABP inserted after induction of anaesthesia but prior to skin incision. The control group received IABP postoperatively in cases of low cardiac index despite inotropic support and adequate filling pressures. After recruiting 110 of a planned 160 patients, the trial was halted early because of futility as there was no significant difference between the groups in the primary endpoint of major morbidity. There was a nonsignificant trend towards lower operative mortality in the IABP group compared with control group [7.3 vs. 14.0%, OR 0.46 (0.13-1.43); P ¼ 0.23] and lower inotropic requirements.
In a retrospective study of IABP in high-risk CABG, Boning et al. [54] found significantly reduced 30-day (5.9 vs. 37.8%) and 2-year mortality (18.1 vs. 54%) in those with preoperative IABP compared with intraoperative insertion. The concept that preoperative IABP is superior to intraoperative IABP was also supported by a meta-analysis [55] .
The evidence base provides limited support for prophylactic IABP insertion in high-risk CABG. Small sample size, variability in inclusion criteria and uncertainty over optimal timing of insertion are all limitations. A larger RCT powered for clinical endpoints would be of value.
CONCLUSION
IABP has been in clinical use for 45 years on the basis of the physiological principles and observational data. Recent systematic reviews, meta-analyses and randomized clinical trials have failed to demonstrate the efficacy of IABP in MI treated with primary PCI with or without shock. Although meta-analysis and RCTs do not support the use of prophylactic IABP in high-risk PCI, long-term follow-up of a recent RCT suggests a late mortality benefit warranting further study. Meta-analysis of several small studies suggests efficacy of prophylactic IABP in high-risk CABG, but there are conflicting data from a recent RCT which was not powered for clinical endpoints.
From time to time in medicine, long-accepted therapies come into question and require re-evaluation. IABP support is in this situation at present. Although the current evidence base has significant limitations, the resulting equipoise creates an ideal environment to embark on large-scale randomized trials of IABP in high-risk MI and shocked MI treated with primary PCI and of prophylactic IABP in highrisk PCI and CABG. Studies should seek to establish appropriate indications and optimal timing of IABP insertion in conjunction with optimal medical therapy and contemporary reperfusion and revascularization strategies. 
